Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nasus PharmaNSRX -3.96%14 Net Debt Paydown Yield % is 4.12% as of Jul. 22, 2026, which is 133% above its 10-year median of 1.77. GuruFocus rates NSRX with a GF Score™ of 14/100. The stock has 4 warning signs investors should review. Among 918 Drug Manufacturers companies, Nasus Pharma ranks better than 85.62% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Nasus Pharma's Net Debt Paydown Yield % was 4.12%.
Nasus Pharma (AMEX:NSRX) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
Nasus Pharma Net Debt Paydown Yield % Related Terms
Nasus Pharma Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for Nasus Pharma's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSRX vs MIRA, SCLX, MDCX: Net Debt Paydown Yield % Comparison
For the Drug Manufacturers - General subindustry, Nasus Pharma's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nasus Pharma Net Debt Paydown Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nasus Pharma's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Nasus Pharma's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 4.12% mean?
Nasus Pharma (NSRX) has a Net Debt Paydown Yield % of 4.12% as of Jul. 22, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Nasus Pharma and its competitors. This is 133% above median its historical median of 1.77. Over the past decade, Nasus Pharma's Net Debt Paydown Yield % has ranged from 1.77 to 4.12. According to the industry distribution chart, Nasus Pharma ranks #132 out of 918 companies in the Drug Manufacturers industry, placing it in the top 14.4%.
Is Nasus Pharma's Net Debt Paydown Yield % too high?
Nasus Pharma's current Net Debt Paydown Yield % of 4.12% is 133% above median its 10-year median of 1.77. Over the past 10 years, this metric has ranged from a low of 1.77 to a high of 4.12. Based on the distribution chart, Nasus Pharma ranks #132 out of 918 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Nasus Pharma has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Nasus Pharma's Net Debt Paydown Yield % compare to MIRA and SCLX?
According to the Drug Manufacturers industry distribution chart, Nasus Pharma ranks #132 out of 918 companies for Net Debt Paydown Yield %. This places Nasus Pharma in the top 14% of its industry — outperforming the majority of peers. Historically, Nasus Pharma's own Net Debt Paydown Yield % has ranged from 1.77 to 4.12 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Drug Manufacturers company?
A good Net Debt Paydown Yield % depends on the Drug Manufacturers industry context. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Nasus Pharma and its competitors. Nasus Pharma's current Net Debt Paydown Yield % is 4.12%, which is 133% above median its own 10-year median of 1.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nasus Pharma stock overvalued right now?
Nasus Pharma (NSRX) has a current Net Debt Paydown Yield % of 4.12%. The current Net Debt Paydown Yield % is 4.12%, which is 133% above median its 10-year median of 1.77. Nasus Pharma's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Nasus Pharma (NSRX), the current Net Debt Paydown Yield % is 4.12% as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.
14GF Score
Get the complete analysis for NSRX
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSRX has been successfully added to your 
